leisure time -WSS

leisure time

author：Wikipedia 2025-10-01 17:21:09 - browse：119

Adam Feuerstein, upper left, moderated a panel with, clockwise, David Chang of Allogene Therapeutics, Rachel Haurwitz of Caribou Biosciences, and Lynelle Hoch of Bristol Myers Squibb. STAT

If you ask biopharma leaders what’s ahead for CAR-T cancer therapy, they say the future is bright. And that future will also look markedly different than it does today, three of them said at the STAT 2023 Future Summit on Wednesday.

Now in its second decade, the cell therapy — which attacks cancer by extracting white blood cells from a patient, genetically modifying them, and then re-infusing them to fight the cancer — has made remarkable strides. Biotech reporter Adam Feuerstein reminded panelists that Emily Whitehead, the first pediatric patient to receive the therapy at age 10, has just started college.

But for all its success in changing the lives of up to 7,000 patients to the point one can use the word “cure,” the field has been hampered by wait lists at manufacturers making these patient-specific, autologous therapies and a shortage of medical centers to administer them. Patients bear a burden, too: Training their B cells to attack their tumors requires an onerous depletion process before their cells can be taken out of their bodies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Ebola: Gilead Sciences antiviral shows promise as new treatment

explore

WSS

AI used to predict Covid

RaDonda Vaught links Vanderbilt hospital issues to patient death

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

HHS secretary Becerra pressed on Change HealthCare cyberattack

Akili, maker of video game for ADHD, to be acquired for 34 million

Amid AI frenzy, a top HHS official's quest to create safeguards

focus

leisure time

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Pushing for an NIH office for post

How one medical school became remarkably diverse

First U.S. drug developed to treat liver disease MASH is approved

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Sports medicine is finally prioritizing gender equality

Heat waves linked to early deliveries, preterm births in new study

United colonoscopy coverage change 'may cost lives,' doctors say

First U.S. drug developed to treat liver disease MASH is approved

focus

First Opinion Podcast: What happens when kids become caregivers?

Akili, maker of video game for ADHD, to be acquired for 34 million

Steward Health Care Massachusetts hospitals face fiscal disaster

iTeos Therapeutics debuts first data on TIGIT

Readout Newsletter: CAR

Focused ultrasound for uterine fibroids: an uphill battle

entertainment

explore

explore

hotspot